What's Happening?
The U.S. Food and Drug Administration (FDA) has approved bemotrizinol for use in American sunscreens, marking the first new active ingredient approval since the 1990s. Bemotrizinol is a chemical compound that provides broad-spectrum protection against
UVA and UVB rays. It has been used in Europe and Asia for decades and is known for its stability and low absorption into the body. The approval process was expedited under the CARES Act, which aims to streamline the approval of over-the-counter drugs. Health and Human Services Secretary Robert F. Kennedy Jr. stated that this move will enhance competition and consumer confidence in sunscreen products.
Why It's Important?
The introduction of bemotrizinol into the U.S. market is a significant development for consumers seeking effective sun protection. Its broad-spectrum capabilities and stability make it a superior option compared to many existing ingredients, which often require frequent reapplication and may absorb into the bloodstream. This approval could lead to increased competition among sunscreen manufacturers, potentially resulting in better products and prices for consumers. Additionally, the availability of bemotrizinol aligns U.S. sunscreen standards more closely with international markets, potentially increasing consumer trust and encouraging more consistent use of sunscreen.
What's Next?
Bemotrizinol-based sunscreens are expected to be available in the U.S. later this year, initially under the brand name Parsol Shield by DSM Nutritional Products. After an 18-month exclusivity period, other manufacturers will be able to introduce their own products containing the ingredient. This could lead to a wider variety of sunscreen options for consumers. The FDA's decision may also pave the way for the approval of other international sunscreen ingredients, further expanding the choices available to American consumers.
